更新于：2024-05-01
Methocarbamol
美索巴莫
更新于：2024-05-01
概要
基本信息
简介以 Robaxin 等品牌名称销售的美索巴莫是一种用于治疗短期肌肉骨骼疼痛的药物。 它可以与休息、物理治疗和止痛药一起使用。 它不太适合用于腰痛。 它对类风湿性关节炎和脑瘫的使用有限。 效果通常在半小时内开始。 口服或静脉注射。 常见的副作用包括头痛、嗜睡和头晕。 严重的副作用可能包括过敏反应、肝脏问题、精神错乱和癫痫发作。 不建议在怀孕和哺乳期间使用。 由于存在受伤风险，老年患者通常应避免使用骨骼肌松弛剂。 美索巴莫是一种中枢性肌肉松弛剂。 它是如何工作的还不清楚，但它似乎不会直接影响肌肉。 |
药物类型 小分子化药 |
别名 (RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate、Methocarbamol (JAN/USP/INN)、Methocarbamol for Suspension + [10] |
靶点 |
作用机制 CA1抑制剂(碳酸酐酶I抑制剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1957-07-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C11H15NO5 |
InChIKeyGNXFOGHNGIVQEH-UHFFFAOYSA-N |
CAS号532-03-6 |
关联
13
项与 美索巴莫 相关的临床试验A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of a Single Administration of F14 for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Replacement
Addition of Methocarbamol to Postoperative Multimodal Analgesic Regimen: A Prospective, Randomized Pilot Study
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
100 项与 美索巴莫 相关的临床结果
登录后查看更多信息
100 项与 美索巴莫 相关的转化医学
登录后查看更多信息
100 项与 美索巴莫 相关的专利（医药）
登录后查看更多信息
265
项与 美索巴莫 相关的文献（医药）2024-02-06BMJ case reports
Atypical neuroleptic malignant syndrome in an incarcerated patient: a demographic who may be at increased risk.
Article
作者: Matthew Zabel ; Rajeev Kandukuri
An incarcerated male patient with a psychiatric history of schizoaffective disorder presented to the emergency department with muscle rigidity and mutism after receiving a 150 mg haloperidol decanoate injection. At the peak of his illness, symptoms included muscular rigidity, mutism, excessive drooling, an altered level of consciousness, tachycardia, diaphoresis and tremors. Atypical neuroleptic malignant syndrome (NMS) was diagnosed after discrediting similar illnesses through clinical reasoning, laboratory and imaging studies. He was successfully treated during a 40-day hospitalisation with lorazepam, amantadine, methocarbamol and supportive care. This case represents an atypical presentation of NMS due to the patient's lack of fever development. Nonetheless, he satisfied many other criteria, most notably rapid symptom onset after receiving a first-generation antipsychotic medication. The case also provides an opportunity to discuss the prevalence of psychiatric illness among the US incarcerated population and incarceration as a risk factor for developing NMS.
2023-10-01Cureus
The Impact of Non-opioid Analgesic Usage on Total Opioid Load During Traumatic Brain Injury Rehabilitation: A Retrospective Study.
Article
作者: Joshua D King ; Kylo Cautivar ; Duc A Tran ; Mohammad Ali ; Nicholas Schmidt ; Michelle McSkane ; Eugene Pak
Background Patients staying in acute rehabilitation often use large amounts of opioids during their stay. There are a number of reasons for this increased opioid exposure, including but not limited to daily exercises with physical and occupational therapists, increased demand on a healing body, and use of previously atrophying musculature. Some physiatrists have noticed that patients who concurrently are prescribed medications such as Robaxin seem to require fewer opioids during their stay in acute rehabilitation. This study aimed to determine the association between non-opioid analgesic use and total opioid load, as measured using morphine milligram equivalents (MMEs), during inpatient rehabilitation for traumatic brain injury. Methodology A retrospective study of individuals with a diagnosis of traumatic brain injury admitted to an acute inpatient rehabilitation program was performed. Non-opioid medications that were reviewed in the study included acetaminophen, amitriptyline, baclofen, diclofenac, gabapentin, ibuprofen, lidocaine, methocarbamol, nortriptyline, and pregabalin. Five of the most-used non-opioid medications (acetaminophen, diclofenac, gabapentin, lidocaine, and methocarbamol) were statistically analyzed using regression and analysis of variance to evaluate for any significant variables. Results Results showed that the average daily dose of acetaminophen has a significant effect on the average daily MME and that the average daily dose of gabapentin and methocarbamol each have a significant effect on the change of daily MME usage from admission to discharge from acute rehab (ΔMME). Results also showed that the mere presence of methocarbamol (regardless of daily or total dosage) had a significant effect on the ΔMME. Conclusions Based on these findings, physicians may want to consider prescribing acetaminophen, gabapentin, or methocarbamol for patients admitted for inpatient rehabilitation following traumatic brain injury who require high amounts of opioids.
2023-08-03Biomedicines
Economic Trends in Commonly Used Drugs for Spinal Fusion and Brain Tumor Resection: An Analysis of the Medicare Part D Database.
Article
作者: Jagroop Doad ; Nithin Gupta ; Lydia Leavitt ; Alexandra Hart ; Andrew Nguyen ; Shawn Kaura ; Frank DeStefano ; Edwin McCray ; Brandon Lucke-Wold
With the incidence of central and peripheral nervous system disorders on the rise, neurosurgical procedures paired with the careful administration of select medications have become necessary to optimize patient outcomes. Despite efforts to decrease the over-prescription of common addictive drugs, such as opioids, prescription costs continue to rise. This study analyzed temporal trends in medication use and cost for spinal fusion and brain tumor resection procedures. The Medicare Part B Database was queried from 2016 to 2020 for data regarding spinal fusion and brain tumor resection procedures, while the Part D Database was used to extract data for two commonly prescribed medications for each procedure. Pearson's correlation coefficient and linear regression were completed for the analyzed variables. The results showed a significant negative correlation between the number of spinal procedure beneficiaries and the cost of methocarbamol, as well as between the annual percent change in spinal beneficiaries and the annual percent change in oxycodone cost. Linear regression revealed that oxycodone cost was the only parameter with a statistically significant model. Moving forward, it is imperative to combat rising drug costs, regardless of trends seen in their usage. Further studies should focus on the utilization of primary data in a multi-center study.
28
项与 美索巴莫 相关的新闻（医药）
100 项与 美索巴莫 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 肌肉骨骼疼痛 | 批准上市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 240 | Naproxen+Placebo | (築蓋鑰襯鬱願艱製遞觸) = 繭鏇鬱窪選艱選蓋餘壓 顧網淵範簾積窪獵鏇鏇 (衊構網顧鹹製醖衊齋淵, 8.9 ~ 12.9) | 不佳 | 2018-03-01 | ||
(築蓋鑰襯鬱願艱製遞觸) = 鹽糧願遞鬱鑰衊顧範鑰 顧網淵範簾積窪獵鏇鏇 (衊構網顧鹹製醖衊齋淵, 7.4 ~ 11.5) | |||||||
N/A | - | (齋壓艱鑰齋齋壓窪衊廠): RR = 1.32 (95% CI, 1.19 ~ 1.44) 更多 | - | 2023-02-01 | |||
临床4期 | 153 | (Placebo Infusion) | 膚壓鑰淵憲鹽淵選艱觸(築繭窪醖顧製鬱衊遞淵) = 顧構鹽顧製鬱製淵衊鹹 憲鹹構蓋膚構窪蓋觸艱 (膚構鏇鹹壓構衊憲窪願, 鑰蓋淵積壓獵襯網簾鏇 ~ 蓋鏇襯簾襯顧憲築憲蓋) 更多 | - | 2020-02-05 | ||
(Ketamine Infusion) | 膚壓鑰淵憲鹽淵選艱觸(築繭窪醖顧製鬱衊遞淵) = 糧範鏇夢鬱遞構夢壓憲 憲鹹構蓋膚構窪蓋觸艱 (膚構鏇鹹壓構衊憲窪願, 遞壓獵夢艱繭繭壓鏇廠 ~ 廠積構鹹鹽築積繭窪觸) 更多 | ||||||
临床4期 | 240 | Placebo+Naproxen (Placebo) | 選糧範齋鹽糧鏇構襯範(獵膚憲獵獵襯窪範觸淵) = 淵鏇鹹鏇夢廠鬱鏇憲觸 鬱網鏇窪齋壓壓鑰齋艱 (憲醖範夢鹹壓遞襯築選, 蓋夢艱遞築獵憲構鏇膚 ~ 觸構窪鏇鏇鏇廠簾鬱艱) 更多 | - | 2018-06-26 | ||
(Orphenadrine) | 選糧範齋鹽糧鏇構襯範(獵膚憲獵獵襯窪範觸淵) = 淵遞構蓋繭選網鏇繭鏇 鬱網鏇窪齋壓壓鑰齋艱 (憲醖範夢鹹壓遞襯築選, 夢壓獵顧夢壓遞窪襯觸 ~ 糧構製構願顧遞餘網膚) 更多 | ||||||
临床3期 | 80 | 餘淵顧壓鹽選顧觸製齋(齋醖夢獵壓膚鏇壓憲襯) = 願鏇鹽襯糧築廠淵鏇淵 夢鬱構構醖膚築膚齋積 (夢衊簾醖選窪簾獵積醖, 築顧糧淵鹽網選鏇醖壓 ~ 顧構簾網醖鹽窪顧餘鹽) 更多 | - | 2018-07-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用